Why Is BioNTech Stock Gaining Monday?
BioNTech (BNTX) Phase 3 data reveals gotistobart almost doubles survival in advanced lung cancer over standard docetaxel.
Stocks · News reference
QUICK SPARK: FDA Approves Updated COVID Vaccines From Moderna, Pfizer, Novavax
FDA approves updated COVID-19 vaccines for 2026-'27 season, targeting XFG variant. Limited eligibility for adults 65+ and those with high-risk conditions.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BioNTech And OncoC4's Gotistobart Shows Hazard Ratio Of 0.56 Versus Docetaxel In PRESERVE-003 Phase 3 Trial For Previously Treated Squamous Non-Small Cell Lung Cancer
Why Pfizer Stock Was so Healthy in August
Pfizer stock surged nearly 14% in August following better-than-expected Q2 earnings (revenue $15B vs. $14.4B expected, EPS $0.77 vs. $0.68 expected) and raised full-year revenue guidance. The company also achieved regulatory victories with EMA validation for a Lyme disease treatment and FDA approval for an updated COVID vaccine. Despite investor impatience over the lack of new blockbuster products, the analyst views Pfizer as undervalued with a promising pipeline from recent acquisitions.
This Best Buy Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Tuesday
Analysts downgraded BioNTech, Gulfport Energy, Amgen and Best Buy; price targets fell for BioNTech and Gulfport.
AMD Hits $1 Trillion, Muse Spooks Subscription Stocks: This Week on Wall Street
AMD crossed $1 trillion and Meta's Muse rattled subscription stocks. Meanwhile, Treasury yields hit 2007 highs.
Moderna Stock Reached New 52-Week High: What's Happening?
Moderna Inc. (NASDAQ: MRNA) shares are trading higher Friday, hitting a fresh 52-week high on anticipation of clinical trial data.